TOP 1902 (Non-Small Cell Lung Cancer) - Clinical Trial
What is the Purpose of this Study?
Treatment
We are doing this study to learn more about the study drug (GT-103) and to find the best dose to give to patients with advanced NSCLC.
What is the Condition Being Studied?
Objective
Advanced Stage Non-Small Cell Lung Cancer
Who Can Participate in the Study?
Key Eligibility
Adults 18+ who:
- Have a diagnosis of advanced non-small cell lung cancer
For more information about who can join this study, please contact the study team at 919-681-4768.
Age Group
Adults
What is Involved?
Description
If you choose to join this study, you will:
- Have a physical exam
- Have blood samples taken
- Get the study drug (GT-103) every 3 weeks as long as you continue to do well and tolerate the drug. The study drug will be given into your arm by an IV.
Once you complete your treatment, you will complete a follow-up phone call every 12 weeks for up to 3 years.
Study Details
Full Title
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00104564
NCT:
NCT04314089
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-681-4768